J. Janetka

M. Mitreva, S. Wildman, J. Janetka, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist

D. Fremont, J. Gordon, J. Pinkner, 2017, Nature.

Aspartyl Protease Inhibitors as Anti-Filarial Drugs

M. Mitreva, J. Janetka, B. Rosa, 2022, Pathogens.

Discovery of novel hedgehog antagonists from cell-based screening: Isosteric modification of p38 bisamides as potent inhibitors of SMO.

J. Janetka, A. Hird, L. Dakin, 2012, Bioorganic & medicinal chemistry letters.

Small Molecule Inhibitors of Metabolic Enzymes Repurposed as a New Class of Anthelmintics.

Xin Gao, M. Mitreva, S. Wildman, 2018, ACS infectious diseases.

Novel Cyclic Biphenyl Ether Peptide β-Strand Mimetics and HIV-Protease Inhibitors

K. Satyshur, P. Raman, J. Janetka, 1997 .

A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131.

S. Beatson, S. Hultgren, T. Hannan, 2013, The Journal of infectious diseases.

Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.

S. Wildman, J. Janetka, P. Harris, 2015, Bioorganic & medicinal chemistry.

Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn’s disease

T. Hannan, J. Janetka, Laurel Mydock-McGrane, 2017, Expert opinion on drug discovery.

Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides.

J. Pinkner, S. Hultgren, J. Janetka, 2012, Journal of medicinal chemistry.

Treatment and Prevention of Urinary Tract Infection with Orally Active FimH Inhibitors

J. Crowley, J. Pinkner, S. Hultgren, 2011, Science Translational Medicine.

Structure-based drug design and optimization of mannoside bacterial FimH antagonists.

S. Wildman, J. Pinkner, S. Hultgren, 2010, Journal of medicinal chemistry.

Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.

Shunqiang Li, L. Klampfer, J. Janetka, 2021, Journal of medicinal chemistry.

Optimizing pyrazolopyrimidine inhibitors of calcium dependent protein kinase 1 for treatment of acute and chronic toxoplasmosis.

L. Sibley, J. Janetka, A. Hopper, 2020, Journal of medicinal chemistry.

C‐Glycosides, Array‐based Addressable Libraries, and the Versatility of Constant Current Electrochemistry

J. Janetka, Jake A. Smith, K. Moeller, 2016 .

Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli

S. Hultgren, Michael E. Hibbing, J. Janetka, 2015, mBio.

Combinatorial Small-Molecule Therapy Prevents Uropathogenic Escherichia coli Catheter-Associated Urinary Tract Infections in Mice

S. Hultgren, K. Dodson, J. Janetka, 2012, Antimicrobial Agents and Chemotherapy.

A host receptor enables type 1 pilus-mediated pathogenesis of Escherichia coli pyelonephritis.

D. Fremont, J. Pinkner, S. Hultgren, 2021, PLoS pathogens.

Precision antimicrobial therapeutics: the path of least resistance?

Scott J. Hultgren, S. Hultgren, J. Janetka, 2018, npj Biofilms and Microbiomes.

A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells

C. Craik, S. Whelan, L. Klampfer, 2021, Proceedings of the National Academy of Sciences.

Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.

S. Wildman, J. Janetka, V. Damalanka, 2019, MedChemComm.

Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.

J. Janetka, V. Damalanka, 2019, Future medicinal chemistry.

Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.

S. Wildman, J. Janetka, W. Shen, 2014, ACS medicinal chemistry letters.

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Stephen Green, B. Caleb, G. Schwartz, 2008, Molecular Cancer Therapeutics.

Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.

J. Breed, V. Oza, P. Lyne, 2012, Journal of medicinal chemistry.

A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells

C. Craik, S. Whelan, L. Klampfer, 2021, bioRxiv.

Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation

L. Klampfer, J. Janetka, B. Owusu, 2017, Oncotarget.

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment

L. Klampfer, J. Janetka, B. Owusu, 2017, Cancers.

Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.

C. Craik, J. Klefström, J. Janetka, 2018, Journal of medicinal chemistry.

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.

Xiaoling Xie, Jingrong Cao, Alex M Aronov, 2009, Journal of medicinal chemistry.

MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A

G. Dorn, R. Kitsis, J. Janetka, 2018, Science.

Click Chemistry Reagent for Identification of Sites of Covalent Ligand Incorporation in Integral Membrane Proteins.

J. Janetka, J. Abramson, A. Evers, 2017, Analytical chemistry.

FimH Inhibitors Treatment and Prevention of Urinary Tract Infection with Orally Active

J. Crowley, J. Pinkner, S. Hultgren, 2011 .

Total Synthesis of the Cyclic Biphenyl Ether Peptides K-13 and OF4949-III via SNAr Macrocyclization of Peptidyl Ruthenium π-Arene Complexes

J. Janetka, D. Rich, 1997 .

Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors.

Xiaoling Xie, Jingrong Cao, Alex M Aronov, 2007, Journal of medicinal chemistry.

Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.

K. Shokat, L. Sibley, J. Janetka, 2017, Journal of medicinal chemistry.

Keeping checkpoint kinases in line: new selective inhibitors in clinical trials.

J. Janetka, S. Ashwell, S. Zabludoff, 2008, Expert opinion on investigational drugs.

Photoaffinity labeling with cholesterol analogues precisely maps a cholesterol-binding site in voltage-dependent anion channel-1

Julian P. Whitelegge, J. Janetka, J. Whitelegge, 2017, The Journal of Biological Chemistry.

A cyclic side-chain-linked biphenyl ether tripeptide: H3N(+)-cyclo-[Phe(4-O)Phe-Phe(3-O)]-OMe.Cl-.

K. Satyshur, J. Janetka, D. Rich, 1996, Acta crystallographica. Section C, Crystal structure communications.

Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation

L. Klampfer, J. Janetka, B. Owusu, 2017, Oncotarget.

Identification of small molecule inhibitors that block the Toxoplasma gondii rhoptry kinase ROP18.

Matthieu Schapira, Scott A Wildman, Emily A Hull-Ryde, 2016, ACS infectious diseases.

Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors.

J. Breed, P. Lyne, J. Janetka, 2018, Journal of Medicinal Chemistry.

L-Selectride as a general reagent for the O-demethylation and N-decarbomethoxylation of opium alkaloids and derivatives

J. Janetka, K. Rice, A. Coop, 1998 .

L-Selectride as a General Reagent for the O-Demethylation and N-Decarbomethoxylation of Opium Alkaloids and Derivatives.

J. Janetka, K. Rice, A. Coop, 2010 .

Distinguishing the Contribution of Type 1 Pili from That of Other QseB-Misregulated Factors when QseC Is Absent during Urinary Tract Infection

S. Hultgren, T. Hannan, J. Janetka, 2012, Infection and Immunity.

Diaryldimethylpiperazine ligands with μ- and δ-opioid receptor affinity: Synthesis of (+)-4-[(αR)-α-(4-allyl-(2S, 5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]- N-ethyl-N-phenylbenzamide and (-)-4-[(αR)-α-(2S, 5S)-dimethylpiperazin-1-yl)-(3-hydroxyphenyl)methyl]-N-ethyl-N -phenylbenzamide

Judith L. Flippen-Anderson, Arthur E. Jacobson, Clifford George, 2003 .

Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI

J. Pinkner, S. Hultgren, V. Kalas, 2016, ChemMedChem.

Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.

J. Breed, V. Oza, P. Lyne, 2010, Bioorganic & medicinal chemistry letters.

Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn’s disease

J. Janetka, Zachary T. Cusumano, Laurel Mydock-McGrane, 2016, Expert opinion on therapeutic patents.

HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis.

S. Pothula, J. Janetka, R. Pirola, 2023, Cancer letters.

Identification of small molecule enzyme inhibitors as broad-spectrum anthelmintics

M. Mitreva, S. Wildman, J. Janetka, 2019, Scientific Reports.

Identification of small molecule enzyme inhibitors as broad- Identification of small molecule enzyme inhibitors as broad-spectrum anthelmintics spectrum anthelmintics Let us know how access to this document benefits you.

M. Mitreva, S. Wildman, J. Janetka, 2021 .

Biphenyl Gal and GalNAc FmlH Lectin Antagonists of Uropathogenic E. coli (UPEC): Optimization through Iterative Rational Drug Design.

J. Pinkner, S. Hultgren, V. Kalas, 2018, Journal of medicinal chemistry.

Checkpoint kinase inhibitors: a review of the patent literature

J. Janetka, S. Ashwell, James W Janetka, 2009, Expert opinion on therapeutic patents.

Combinatorial Small-molecule Therapy Prevents Uropathogenic Escherichia Coli Catheter-associated Urinary Tract Infections in Mice Recommended Citation Infections in Mice Catheter-associated Urinary Tract Prevents Uropathogenic Escherichia Coli Combinatorial Small-molecule Therapy Supplemental Materi

S. Hultgren, K. Dodson, J. Janetka, 2022 .

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

B. Caleb, G. Schwartz, J. Janetka, 2008, Molecular Cancer Therapeutics.

Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.

G. Bemis, F. Maltais, J. Janetka, 2009, Journal of medicinal chemistry.

Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.

P. Lyne, J. Janetka, S. Ashwell, 2008, Bioorganic & medicinal chemistry letters.

Hepsin promotes breast tumor growth signaling via the TGFβ‐EGFR axis

T. Tervonen, J. Klefström, J. Janetka, 2023, Molecular oncology.

Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer

J. Janetka, J. Higginbotham, V. Damalanka, 2024, Cellular and molecular life sciences : CMLS.

Synthesis of peptidyl ruthenium .pi.-arene complexes: application to the synthesis of cyclic biphenyl ether peptides.

J. Janetka, D. Rich, 1995 .